Skye Bioscience (SKYE) Short term Debt (2017 - 2026)
Skye Bioscience (SKYE) posted quarterly Short term Debt of $250338.0 for Q1 2026, down 86.91% year-over-year from $1.9 million in Q1 2025, and down 87.81% quarter-over-quarter from $2.1 million in Q3 2025.
Skye Bioscience (SKYE) Short term Debt (2017 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Short term Debt for 9 consecutive years, with $250338.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt fell 86.91% year-over-year to $250338.0; the TTM figure through Mar 2026 stood at $250338.0 (down 86.91% YoY), while the FY2024 annual figure was $1.8 million, down 58.4% from the prior year.
- Short term Debt fell to $250338.0 in Q1 2026 per SKYE's latest filing, from $2.1 million in the prior quarter.
- Across five years, Short term Debt topped out at $6.2 million in Q3 2023 and bottomed at $30615.0 in Q3 2022.
- Historically, Short term Debt has averaged $3.0 million across 5 years, with a median of $2.0 million in 2025.
- Annual changes were most pronounced in 2023 — Short term Debt soared 20191.75% — and 2026, when it tumbled 86.91%.
- Skye Bioscience's Short term Debt stood at $6.2 million in 2022, then declined by 29.54% to $4.4 million in 2023, then slumped by 58.4% to $1.8 million in 2024, then rose by 12.95% to $2.1 million in 2025, then tumbled by 87.81% to $250338.0 in 2026.
- Business Quant data shows SKYE's Short term Debt at $250338.0 in Q1 2026, $2.1 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - |
| 10 | Skye Bioscience | 10.72 Mn | 10.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 250,338.00 |
| Sep 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Jun 30, 2024 | 6.05 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 6.21 Mn |
| Mar 31, 2023 | 6.21 Mn |
| Dec 31, 2022 | 6.21 Mn |
| Sep 30, 2022 | 30,615.00 |
| Jun 30, 2022 | 122,461.00 |
| Mar 31, 2022 | 450,000.00 |
| Mar 31, 2021 | 103,523.00 |
| Dec 31, 2020 | 64,062.00 |
| Sep 30, 2020 | 71,102.00 |
| Jun 30, 2020 | 51,653.00 |
| Dec 31, 2018 | 1.36 Mn |
| Dec 31, 2017 | 235,000.00 |